Vinpocetin hatása krónikus agyérbetegségben szenvedók hemoreológiai viszonyaira.

Translated title of the contribution: Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease

L. Szapáry, B. Horváth, Tamás Alexy, Zsolt Márton, Gábor Késmárky, Mónika Szóts, Ferenc Nagy, József Czopf, K. Tóth

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

INTRODUCTION: Data collected from large number of multicenter, randomized trials in acute and chronic stroke patients provide evidence, that incidence and high mortality of cerebrovascular disorders can be decreased mainly by prevention and that the effectiveness of acute stroke treatment is limited. The terminology of "chronic cerebrovascular diseases" involves many pathologic entities and often atypical clinical symptoms refer to the focal or global hypoperfusion of the brain. However, hemorheological disturbances seem to be important factors of the complex pathomechanism. Vinpocetine has successfully been used in the treatment of cerebrovascular diseases, the part of the mechanism of action are the favourable rheological effects demonstrated after oral administration in more previous studies. AIMS AND METHODS: In this study the hemorheological changes after administration of small (30 mg/day) and high dose (increased to 70 mg/day) intravenous vinpocetine for 7 days in 30 patients in chronic phase of ischemic cerebrovascular disease were investigated. RESULTS: High dose parenteral vinpocetine treatment significantly (p <0.05-0.005) decreased the hematocrit, the whole blood and plasma viscosity and red blood cell aggregation compared to the values before the treatment. Only red blood cell aggregation was improved significantly (p <0.05) by small dose treatment. CONCLUSION: This study and other hemorheological studies in cerebrovascular patients demonstrated persistent rheological abnormalities despite the preventive therapy. The beneficial rheological effect of high dose parenteral vinpocetine indicates the use of this drug in the treatment of chronic cerebrovascular diseases.

Original languageHungarian
Pages (from-to)973-978
Number of pages6
JournalOrvosi Hetilap
Volume144
Issue number20
Publication statusPublished - May 18 2003

Fingerprint

Cerebrovascular Disorders
vinpocetine
Chronic Disease
Cell Aggregation
Therapeutics
Erythrocytes
Stroke
Blood Viscosity
Hematocrit
Terminology
Multicenter Studies
Oral Administration
Mortality
Incidence
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vinpocetin hatása krónikus agyérbetegségben szenvedók hemoreológiai viszonyaira. / Szapáry, L.; Horváth, B.; Alexy, Tamás; Márton, Zsolt; Késmárky, Gábor; Szóts, Mónika; Nagy, Ferenc; Czopf, József; Tóth, K.

In: Orvosi Hetilap, Vol. 144, No. 20, 18.05.2003, p. 973-978.

Research output: Contribution to journalArticle

Szapáry, L, Horváth, B, Alexy, T, Márton, Z, Késmárky, G, Szóts, M, Nagy, F, Czopf, J & Tóth, K 2003, 'Vinpocetin hatása krónikus agyérbetegségben szenvedók hemoreológiai viszonyaira.', Orvosi Hetilap, vol. 144, no. 20, pp. 973-978.
Szapáry L, Horváth B, Alexy T, Márton Z, Késmárky G, Szóts M et al. Vinpocetin hatása krónikus agyérbetegségben szenvedók hemoreológiai viszonyaira. Orvosi Hetilap. 2003 May 18;144(20):973-978.
Szapáry, L. ; Horváth, B. ; Alexy, Tamás ; Márton, Zsolt ; Késmárky, Gábor ; Szóts, Mónika ; Nagy, Ferenc ; Czopf, József ; Tóth, K. / Vinpocetin hatása krónikus agyérbetegségben szenvedók hemoreológiai viszonyaira. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 20. pp. 973-978.
@article{94b2d554141f4bfe8b057850a556c1db,
title = "Vinpocetin hat{\'a}sa kr{\'o}nikus agy{\'e}rbetegs{\'e}gben szenved{\'o}k hemoreol{\'o}giai viszonyaira.",
abstract = "INTRODUCTION: Data collected from large number of multicenter, randomized trials in acute and chronic stroke patients provide evidence, that incidence and high mortality of cerebrovascular disorders can be decreased mainly by prevention and that the effectiveness of acute stroke treatment is limited. The terminology of {"}chronic cerebrovascular diseases{"} involves many pathologic entities and often atypical clinical symptoms refer to the focal or global hypoperfusion of the brain. However, hemorheological disturbances seem to be important factors of the complex pathomechanism. Vinpocetine has successfully been used in the treatment of cerebrovascular diseases, the part of the mechanism of action are the favourable rheological effects demonstrated after oral administration in more previous studies. AIMS AND METHODS: In this study the hemorheological changes after administration of small (30 mg/day) and high dose (increased to 70 mg/day) intravenous vinpocetine for 7 days in 30 patients in chronic phase of ischemic cerebrovascular disease were investigated. RESULTS: High dose parenteral vinpocetine treatment significantly (p <0.05-0.005) decreased the hematocrit, the whole blood and plasma viscosity and red blood cell aggregation compared to the values before the treatment. Only red blood cell aggregation was improved significantly (p <0.05) by small dose treatment. CONCLUSION: This study and other hemorheological studies in cerebrovascular patients demonstrated persistent rheological abnormalities despite the preventive therapy. The beneficial rheological effect of high dose parenteral vinpocetine indicates the use of this drug in the treatment of chronic cerebrovascular diseases.",
author = "L. Szap{\'a}ry and B. Horv{\'a}th and Tam{\'a}s Alexy and Zsolt M{\'a}rton and G{\'a}bor K{\'e}sm{\'a}rky and M{\'o}nika Sz{\'o}ts and Ferenc Nagy and J{\'o}zsef Czopf and K. T{\'o}th",
year = "2003",
month = "5",
day = "18",
language = "Hungarian",
volume = "144",
pages = "973--978",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "20",

}

TY - JOUR

T1 - Vinpocetin hatása krónikus agyérbetegségben szenvedók hemoreológiai viszonyaira.

AU - Szapáry, L.

AU - Horváth, B.

AU - Alexy, Tamás

AU - Márton, Zsolt

AU - Késmárky, Gábor

AU - Szóts, Mónika

AU - Nagy, Ferenc

AU - Czopf, József

AU - Tóth, K.

PY - 2003/5/18

Y1 - 2003/5/18

N2 - INTRODUCTION: Data collected from large number of multicenter, randomized trials in acute and chronic stroke patients provide evidence, that incidence and high mortality of cerebrovascular disorders can be decreased mainly by prevention and that the effectiveness of acute stroke treatment is limited. The terminology of "chronic cerebrovascular diseases" involves many pathologic entities and often atypical clinical symptoms refer to the focal or global hypoperfusion of the brain. However, hemorheological disturbances seem to be important factors of the complex pathomechanism. Vinpocetine has successfully been used in the treatment of cerebrovascular diseases, the part of the mechanism of action are the favourable rheological effects demonstrated after oral administration in more previous studies. AIMS AND METHODS: In this study the hemorheological changes after administration of small (30 mg/day) and high dose (increased to 70 mg/day) intravenous vinpocetine for 7 days in 30 patients in chronic phase of ischemic cerebrovascular disease were investigated. RESULTS: High dose parenteral vinpocetine treatment significantly (p <0.05-0.005) decreased the hematocrit, the whole blood and plasma viscosity and red blood cell aggregation compared to the values before the treatment. Only red blood cell aggregation was improved significantly (p <0.05) by small dose treatment. CONCLUSION: This study and other hemorheological studies in cerebrovascular patients demonstrated persistent rheological abnormalities despite the preventive therapy. The beneficial rheological effect of high dose parenteral vinpocetine indicates the use of this drug in the treatment of chronic cerebrovascular diseases.

AB - INTRODUCTION: Data collected from large number of multicenter, randomized trials in acute and chronic stroke patients provide evidence, that incidence and high mortality of cerebrovascular disorders can be decreased mainly by prevention and that the effectiveness of acute stroke treatment is limited. The terminology of "chronic cerebrovascular diseases" involves many pathologic entities and often atypical clinical symptoms refer to the focal or global hypoperfusion of the brain. However, hemorheological disturbances seem to be important factors of the complex pathomechanism. Vinpocetine has successfully been used in the treatment of cerebrovascular diseases, the part of the mechanism of action are the favourable rheological effects demonstrated after oral administration in more previous studies. AIMS AND METHODS: In this study the hemorheological changes after administration of small (30 mg/day) and high dose (increased to 70 mg/day) intravenous vinpocetine for 7 days in 30 patients in chronic phase of ischemic cerebrovascular disease were investigated. RESULTS: High dose parenteral vinpocetine treatment significantly (p <0.05-0.005) decreased the hematocrit, the whole blood and plasma viscosity and red blood cell aggregation compared to the values before the treatment. Only red blood cell aggregation was improved significantly (p <0.05) by small dose treatment. CONCLUSION: This study and other hemorheological studies in cerebrovascular patients demonstrated persistent rheological abnormalities despite the preventive therapy. The beneficial rheological effect of high dose parenteral vinpocetine indicates the use of this drug in the treatment of chronic cerebrovascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=0037676121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037676121&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 973

EP - 978

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 20

ER -